Edwards Lifesciences (EW) 10-K Summary — Year Ended Dec 31, 2024
Edwards Lifesciences filed its annual report covering the most recent fiscal year. The filing includes financial metrics but lacks detailed business and risk descriptions.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Edwards Lifesciences filed its annual report covering the most recent fiscal year. The filing includes financial metrics but lacks detailed business and risk descriptions.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$5.4B
Revenue reported for the fiscal year.
Operating income
$1.4B
Income from operations reported for the year.
Net income
$4.2B
Net income reported for the year.
Operating cash flow
$542.3M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $1.3B | n/a |
| Jun 30, 2024 | $1.4B | +3.0% |
| Sep 30, 2024 | $1.4B | -1.1% |
| Dec 31, 2024 | $5.4B | +301.6% |
Business overview
The filing does not include a business description for Edwards Lifesciences Corporation.
Financial performance
Annual revenue was reported at a level that suggests a large increase from the previous quarter's run rate. Net income was substantially higher than operating income, and operating cash flow was significantly lower than net income.
Material risks
No risk factors are detailed in the supplied filing context.
Liquidity and capital
The company cites cash, cash equivalents, short-term investments, operating cash flow, and credit facilities as liquidity sources. It believes these are sufficient to fund working capital, capital expenditures, and other commitments, and it periodically considers financing alternatives. A transition tax liability under the Tax Cuts and Jobs Act is payable in remaining annual installments.
What to watch
Monitor the remaining annual installments of the transition tax liability.